Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BIBoehringer Ingelheim

Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy

Columbia ChinaSwire Pacific

Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia

NovartisNYSE: NVS

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

BDgene TechnologyHKG: 2607

Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development

Show More